Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Qarziba Market Size Forecast: How Big Could The Market Get By 2030?
Historical expansion has been driven by a rising prevalence of high-risk neuroblastoma cases, progress in monoclonal antibody development, an increase in pediatric oncology treatment centers, superior survival rates achieved with immunotherapy, and regulatory approvals for specific cancer therapies.
The anticipated growth over the forecast period is fueled by the expansion of precision oncology research, the increasing adoption of GD2-targeted therapies, rising investments in pediatric cancer immunotherapy, a growing emphasis on personalized treatment protocols, and broader global access to advanced oncology drugs.
Significant trends foreseen for the forecast period include the expanding uptake of targeted immunotherapy, the increasing utilization of monoclonal antibodies in pediatric oncology, a heightened focus on relapse prevention therapies, the rising integration of immunotherapy into multimodal treatment regimens, and improved clinical monitoring of treatment outcomes.
Get A Free Sample Report With In-Depth Market Insights:
Qarziba Market Growth Drivers: What’s Behind The Acceleration?
The qarziba market is anticipated to expand due to the escalating incidence of cancer. This rise in cancer cases is linked to factors such as an aging demographic, changes in lifestyle including smoking, inadequate diet, insufficient physical activity, and inherited predispositions. Qarziba (dinutuximab beta) is utilized in pediatric oncology for the management of high-risk neuroblastoma, working by targeting GD2-expressing cancer cells to enhance immune destruction and diminish the likelihood of relapse in this aggressive cancer. For example, a report released by the Australian Institute of Health and Welfare in August 2024 indicates that Australia is expected to register approximately 209,000 new cancer diagnoses by 2034, marking a substantial increase from the 169,000 cases projected for 2024, which illustrates the effect of population growth and increasing cancer rates. Consequently, the growing prevalence of cancer is forecasted to boost the qarziba market.
Qarziba Market Segment Analysis Spotlighting Growth Areas
The qarziba market covered in this report is segmented –
1) By Indication: High-Risk Neuroblastoma, Relapsed Or Refractory Neuroblastoma
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End User: Hospitals, Specialized Oncology Clinics
Qarziba Market Trends: What’s Defining The Industry’s Next Phase?
Leading firms in the Qarziba market are embracing a strategic collaboration strategy to improve technological integration and extend their market presence. This type of alliance generally involves two or more entities working together, pooling their resources, knowledge, and endeavors to accomplish shared aims or targets. As an illustration, in July 2024, Farma Mondo Hong Kong Ltd., which is a Hong Kong-based branch of the Switzerland-based Farma Mondo Group focused on market entry and specialty pharmaceutical distribution, revealed an exclusive licensing and distribution arrangement with Recordati UK Ltd. for Qarziba (dinutuximab beta) within Hong Kong. According to this pact, Farma Mondo Hong Kong will take on the position of the local marketing authorization holder and manage the commercial dissemination of the neuroblastoma therapy throughout the market. Recordati UK Ltd. operates as a pharmaceutical company based in the UK.
Qarziba Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the qarziba market are EUSA Pharma (UK) Ltd
View The Full Qarziba Market Report:
Qarziba Market Geographic Distribution And Regional Opportunities
North America was the largest region in the qarziba market in 2025. The regions covered in the qarziba market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
